GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » ROC (Joel Greenblatt) %

Translate Bio (Translate Bio) ROC (Joel Greenblatt) % : 93.06% (As of Jun. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Translate Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was 93.06%.

The historical rank and industry rank for Translate Bio's ROC (Joel Greenblatt) % or its related term are showing as below:

TBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1054.12   Med: -585.81   Max: 55.08
Current: 55.08

During the past 5 years, Translate Bio's highest ROC (Joel Greenblatt) % was 55.08%. The lowest was -1054.12%. And the median was -585.81%.

TBIO's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -338.875 vs TBIO: 55.08

Translate Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Translate Bio ROC (Joel Greenblatt) % Historical Data

The historical data trend for Translate Bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio ROC (Joel Greenblatt) % Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
-551.59 -1,054.12 -930.62 -585.81 -12.11

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -345.15 213.41 35.07 -78.87 93.06

Competitive Comparison of Translate Bio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Translate Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Translate Bio's ROC (Joel Greenblatt) % falls into.



Translate Bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 21.547) - (29.883 + 72.627 + 3.425)
=-84.388

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 25.784) - (23.489 + 41.014 + 5.326)
=-44.045

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Translate Bio for the quarter that ended in Jun. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2021  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=81.004/( ( (87.717 + max(-84.388, 0)) + (86.372 + max(-44.045, 0)) )/ 2 )
=81.004/( ( 87.717 + 86.372 )/ 2 )
=81.004/87.0445
=93.06 %

Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Translate Bio  (NAS:TBIO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Translate Bio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Translate Bio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109